New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
07:47 EDTDVAXDynavax a compelling buy at current levels, says Jefferies
Jefferies views Dynavax as a risky but compelling buy at current levels following the negative FDA panel vote on the company's hepatitis B vaccine. The firm lowered its price target for shares to $5 from $5 and keeps a Buy rating on the stock.
News For DVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2015
08:17 EDTDVAXDynavax 4.55M share Spot Secondary priced at $27.50
Cowen, RBC Capital and William Blair acted as joint book running managers for the offering.
July 21, 2015
16:02 EDTDVAXDynavax files to sell common stock, no amount given
Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with completing the ongoing Phase 3 HBV-23 study of HEPLISAV-B(TM), seeking regulatory approval of HEPLISAV-B in the United States, and preparing for the anticipated U.S. commercial launch of HEPLISAV-B, should HEPLISAV-B gain approval by the Food and Drug Administration. In addition, net proceeds from the offering will support continuing the clinical development of our investigational cancer immunotherapeutic product candidate, SD-101, and for other general corporate purposes, including working capital. Cowen and Company, RBC Capital Markets and William Blair are acting as joint book-running managers for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use